Abbott Laboratories’ dominance in the coronary stent market is protected

Finnegan client Abbott Laboratories's motion to enforce a settlement agreement with Medinol Ltd. was granted after the court adopted Abbott's interpretation of a settlement between the parties, which gave Abbott an unrestricted license to Medinol's stent patents. After a two-week jury trial on the validity of Medinol's remaining patent claims (but before the jury verdict was announced), the parties settled. When a disagreement arose over a material term during the drafting of the settlement agreement, Finnegan went back to court to enforce the agreement as the parties had stated on the record.